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Abstract 
Presbyopia is an age-related eye condition where one of the signs is the reduction in the 
amplitude of accommodation, resulting in the loss of ability to change the eye’s focus from 
far to near. It is the most common age-related ailments affecting everyone around their mid-
forties. Methods for the correction of presbyopia include contact lens and spectacle options 
but the surgical correction of presbyopia still remains a significant challenge for refractive 
surgeons. Surgical strategies for dealing with presbyopia may be extraocular (corneal or 
scleral) or intraocular (removal and replacement of the crystalline lens or some type of 
treatment on the crystalline lens itself). There are however a number of limitations and 
considerations that have limited the widespread acceptance of surgical correction of 
presbyopia. Each surgical strategy presents its own unique set of advantages and 
disadvantages. For example lens removal and replacement with an intraocular lens may not 
be preferable in a young presbyopic patient without a refractive error. Similarly treatment on 
the crystalline lens may not be a suitable choice for a patient with early signs of cataract. 
This article is a review of the options available and those that are in development stages and 
are likely to be available in the near future for the surgical correction of presbyopia. 
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I. Introduction 
Presbyopia is an age-related reduction in the amplitude of accommodation and leads to the 
loss of ability in changing the eyes focus between far and near. The correction of presbyopia 
without resorting to spectacles and contact lenses remains the Holy Grail for refractive 
surgeons as well as the billions of presbyopes.  
Numerous accommodative and pseudo-accommodative approaches to treat presbyopia 
surgically exist. Each has its own benefits and limitations, and may involve some degree of 
compromise between the distance and near visual acuity (VA). Accommodative approaches 
attempt to restore the true, dynamic and continuous range of the defocusing ability of the 
eye. Pseudo-accommodative approaches provide functional near vision from a variety of 
non-accommodative factors.  
This review provides an overview of the options that are currently available for the surgical 
management of presbyopia. 
 
II. PSEUDO-ACCOMMODATIVE APPROACHES 
1. Corneal Approaches 
1.1. Excimer Laser Procedures 
1.1.1 Monovision  
Monovision with an excimer laser is a well-established technique that corrects one eye for 
distance (usually dominant eye) and the other eye for near, resulting in intentional 
anisometropia. (1) This aim is to give functional near and distant VA without the need for 
glasses. The mechanism that enables monovision to succeed is interocular blur suppression.  
Studies have reported success rates ranging from 80-98% (1,2,3,4,5) for monovision post 
laser vision correction (LVC), 91% for monovision after cataract surgery and 95% following 
clear lens extraction (6) with good satisfaction. Surgically induced monovision is associated 
with a higher success rates than with contact lenses (91-98%), but it is unclear whether this is 
because it is harder to reverse the procedure or because of a multifocal corneal shape in 
LVC. 
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Limitations of monovosion include compromising visual function, such as reduced low 
contrast VA and sensitivity (CS), inability to incorporate an intermediate correction without 
compromising distance or near vision, reduced stereopsis, and small-angle esotropic shift. (2, 
7, 8, 9) 
1.1.2 Multifocal Corneal Ablation  
Multifocality achieved by excimer ablation sometimes known as PresbyLasik, is interesting 
to refractive surgeons because it is familiar, seems less invasive than intraocular surgery and 
could theoretically be more controllable. However, this is against the conventional thinking 
for laser vision correction (LVC) where one usually attempts to minimise the higher order 
aberrations. 
A variety of presbyopic LVC procedures exist. (10, 11, 12) In peripheral prebyopic LVC, the 
peripheral cornea is ablated to create negative peripheral asphericity. Thus the central cornea 
is for distance and mid-periphery for near vision (e.g. Nidek Advanced Vision Excimer 
Laser; (NIDEK Co Ltd, Gamagori, Japan). (11) In central presbyopic LVC, the central area 
is ablated for near vision and periphery for distance (e.g. Supracor, Technolas Perfect Vision 
GmbH, München, Germany); and Pulsar (CustomVis, CV Laser Pty Ltd, Perth, Australia). 
Although optically the results are predictable and good, some patients find it difficult to 
adapt to the compromise and others are dissatisfied by the minor loss of distance VA. (12, 
13) 
Presbyond Laser Blended Vision (Carl Zeiss Meditec, Jena, Germany) is an optimised laser 
treatment method attempting to improve on conventional monovision. The dominant eye is 
treated for distance vision to almost plano and the non-dominant eye is corrected to be 
slightly myopic for near vision to -1.5D. This monovision treatment is enhanced by the use 
of a wavefront-optimised ablation profile to create a continuous refractive power gradient for 
the whole optical zone of the cornea. Studies show that this treatment is a well-tolerated and 
effective procedure for treating patients with presbyopia. (14,15,16) 
 
 
More recently, SCHWIND eye-tech-solutions (Kleinostheim, Germany) introduced its 
PresbyMAX software. This is a bi-aspheric cornea modulation technique, based on the 
creation of a central hyper-positive area for near and leaving the peri-central cornea for far. 
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Uthoff et al. (17) reported good visual outcomes at distance and near in a 6-months follow-
up study (table 1).  
Whilst multifocal LVC represent a promising avenue for future presbyopic correction, 
outcome data is relatively sparse compared to other modalities. (7, 18) 
1.2. Conductive Keratoplasty  
Conductive Keratoplasty (CK) is the successor of Laser Thermokeratoplasty. CK uses the 
application of low frequency radio waves to “shrink” collagen fibrils within the mid-
peripheral cornea. This causes a net steepening on the central cornea and thus increases the 
positive power of the eye. Radiofrequency energy is typically 0.6 W with a 0.6-second 
treatment time, (19) delivered through a fine tip inserted into the peripheral corneal stroma in 
a ring pattern outside of the visual axis. 8 to 32 treatment spots are placed in up to 3 rings in 
the corneal periphery (6-, 7-, and 8-mm optical zones) and striae form between the spots and 
create a band of tightening to steepen the cornea primarily to create monovision. Although 
this has shown to be a relatively safe technique and may present theoretical advantages over 
flap creation techniques (less invasive and no flap related complications), long-term studies 
report high rate of regression and hence this is not a popular technique at present. (20, 21, 22, 
23)  
 
1.3. Intrastromal Femtosecond Ring Incisions 
Although the primary application of femtosecond laser has been its use in the creation of 
Laser-Assisted in situ Keratomileusis (LASIK) flaps, its precision and safety features makes 
it a useful tool for many types of corneal refractive surgery, including intrastromal 
treatments. Typically, 5 concentric rings in the cornea stroma between 2 and 4mm from the 
line of sight are created using a femtosecond laser. Studies with INTRACOR (Technolas 
Perfect Vision GmbH, München, Germany) have shown the technique to be efficient and 
safe. (24, 25) 
The main advantage of INTRACOR is that the corneal surface is not cut. The ring structure 
induces a localized biomechanical change in the tissue causing a slight central steepening of 
1 to 2 diopters (D). This steepening changes the spherical aberration (SA) and corneal 
asphericity, resulting in near vision improvement. (24, 25, 26, 27) To date, the results 
reported have shown an overall improvement of uncorrected near VA (UCNVA). (24, 25, 
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26, 27, 28) However, some studies report no improvement in UCNVA at 1 month (25, 28), 
reduced best distance corrected VA (BDCVA), (26, 28) and anterior corneal protrusion after 
hyperopic LASIK followed by INTRACOR. (29) The treatment is usually performed in the 
non-dominant eye only. Further study is required on this treatment modality. 
 
1.4. Corneal Inlays 
Corneal Inlays (CI) are intrastromal implants which are placed underneath a LASIK flap or 
into a femtosecond laser created corneal pocket. The pocket technique has a number of 
potential advantages: the majority of peripheral corneal nerves are preserved, allowing 
corneal sensitivity to be maintained, they are additive, do not remove tissue, preserve future 
options for presbyopic correction and may be used in pseudophakia and/or combined with 
LVC. (30) In addition, they are all removable. The LASIK flap could be created with a 
microkeratome or with a femtosecond laser. 
Complications reported with CI include hyperopic shift, haloes, a decrease in photopic and 
mesopic contrast sensitivity (CS), corneal thinning and melting, broadened defocus curve 
and reduced simulated retinal blur in the implanted eye (Kamra Inlay, AcuFocus, Irvine, CA) 
(31, 32, 33, 34). With all inlay designs, centration is critical for proper performance, and a 
small displacement can make a clinically significant difference. (35) 
At present, there are three types of corneal inlays: 
- CI that alter the index of refraction with a bifocal optic. The Flexivue Microlens, (Presbia, 
Los Angeles, CA) and Icolens (Neoptics AG, Hunenberg, Switzerland) both are currently in 
clinical trials although several presented studies. The Flexivue (precursor was the Invue) is 
the only CI utilizing a refractive addition power. (36)  
The Icolens is a new CI and recently Baily has reported the one-year visual outcomes (Table 
1). (37) 
- The Raindrop Near Vision Inlay (ReVision Optics, Lake Forest, CA) is a CI that changes 
the corneal curvature. Garza et al. (38) reported good and stable results at 1 year. Table 1. 
- The Kamra CI relies on small-aperture optics to increase the depth of focus. Most of the 
published data demonstrates that monocular implantation of a small-aperture inlay results in 
sustained improvement in near and intermediate vision while maintaining good distance 
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vision. (31, 32, 33, 34) However, the size, material and visibility of the Kamra CI can be a 
disadvantage compared to the other CI. 
2. Lenticular Approaches 
The ultimate goal of cataract and clear lens extraction is to replace the crystalline lens with 
an intraocular lens (IOL) that simulates the original function of the crystalline lens and 
provides the patients with a full range of functional vision for all distances. Currently, the 
available IOLs can be grouped into accommodating (AIOLs) or pseudo-accommodating 
IOLs (although the mechanism of action of some ‘accommodative lenses’ may be pseudo-
accommodative in nature). With pseudo-accommodative multifocal IOLs (MIOLs), the 
patient has 2 or 3 points in focus but primarily perceives only the focused image of interest. 
(39, 40) 
Precise biometry, accurate IOL power calculation, good surgical technique as well as patient 
selection are crucial in achieving the best visual outcome and patient satisfaction.  
 
2.1. Pseudophakic Multifocal Intraocular Lens 
Multifocal Intraocular lenses are used following cataract patients or in clear lens extraction 
(41) and excellent clinical outcomes have been reported. (42, 43) However, patient 
dissatisfaction and secondary procedures, including IOL exchange, can also be significant. 
(44, 45) Some of the MIOLs are based on multifocal contact lens (CL) designs, however the 
visual results may defer between them. First, CLs and IOLs are placed in different location 
in the eye which results in different plane correction and second, the CL moves during the 
blink versus the stability of IOL. These differences could lead to different visual outcomes. 
Complications of theses MIOLs lenses include reduction in quality of vision, especially loss 
of CS, dysphotopsia, and reduced intermediate and near vision. (46)   
The discussion below is not an exhaustive list of the IOLs available or publications (it is 
beyond the scope of this article) but is representative for the common lenses used.  
 
2.1.1. Refractive Multifocal Intraocular Lens 
Refractive MIOLs have the incorporation of 2 different powers integrated into 2 or more 
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typically circular refractive zones. Due to each lens zone having a different effective 
aperture, the image quality can depend on the pupillary response to light and the 
accommodation reflex. (47)  
The ReZoom (AMO, Irvine, California, USA) is a refractive MIOL (the original model being 
called the ARRAY) and the FDA approved it in 2005. It is a three-piece MIOL and has five 
refractive optical zones; zones 1, 3, and 5 are adjusted for far vision, while zones 2 and 4 are 
adjusted for near vision. This design gives good distance vision and good intermediate range 
vision although the reading performance is variable. (48) Disadvantages of this lens, like 
many MIOLs, include dysphotopsia. (49)  
The M-flex MIOL (Rayner IOLs Limited, Hove, UK) is based on a multi-zoned refractive 
aspheric optic technology, with either 4 or 5 annular zones (depending on IOL base power) 
providing +3.0D or +4.0D of additional refractive power at the IOL plane (equivalent to 
+2.25D or +3.0D at the spectacle plane). Cezon et al. (50) reported good visual performance 
and high rate of spectacle independence at 1 year.  
Refractive MIOLs appear to be associated with more photic phenomena compared to 
diffractive MIOLs. (51) Photic phenomena are among the most frequent reasons for patient 
dissatisfaction following implantation of MIOLs. (44, 52)  
 
2.1.2. Diffractive Multifocal Intraocular Lens 
These are based on the principle of diffraction, whereby light slows down and changes 
direction when it encounters an obstacle. (53) These lenses use microscopic steps (diffractive 
zones) across the lens surface. As light encounters these steps, it is directed towards the 
distant and near focal points (the amount of light is directly related to the step height as a 
proportion of wavelength). Diffractive MIOLs can be subdivided into apodized (gradual 
reduction in diffractive step heights from centre to periphery) or non-apodized (uniform 
height): both categories are designed to reduce the severity of night halos compared to 
refractive MIOLs. (54) Examples include the ReSTOR (Alcon Lab Inc. Fort Worth, TX) 
(apodized) and Tecnis Multifocal (Abbott Medical Optics, Santa Ana, CA) and AT LISA 
809 IOL (Carl Zeiss Meditec, Hennigsdorf, Germany) (both non-apodized). Most studies 
report good and stable distance and near vision, leading to low spectacle dependence and 
high patient satisfaction. (55, 56, 57) Although these designs have good visual outcomes, 
their weakest points can be their inability to provide good levels of vision at intermediate 
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distance and loss of CS. 
Aiming to improve intermediate vision, trifocal MIOL designs were introduced to the 
market: AT Lisa tri 839MP novel design (Carl Zeiss Meditec, Hennigsdorf, Germany), 
FineVision (PhysIOL SA, Liège, Belgium), and MIOL-Record trifocal IOL (Reper NN, 
Nizhny Novgorod, Russia). Results reported so far of theses lenses show a significant 
improvement in uncorrected VA at all distances. The trifocal designs may be the emerging 
technology in the field of the diffractive IOLs. (58, 59) The prevalence of complications still 
needs to be assessed with larger clinical studies.  
2.1.3. Rotationally Asymmetric Multifocal Intraocular Lens 
All traditional MIOLs are based on the concept of rotational symmetry. Recently, MIOLs 
with rotational asymmetry were introduced. One such lens, the Lentis MPlus LS-312 
(Oculentis GmbH, Berlin, Germany), consists of a single-piece, aspheric surface that is 
independent of pupil size. (60) Different near additions are available allowing customisations 
for each individual and can be used with a mix and match philosophy. 
Results indicate good distance, intermediate, and near VA with a high level of CS. (61, 62, 
63) The authors recently conducted a study with the latest version: Lentis Mplus X LS-313 
in 34 eyes showing excellent visual performance (64) (Table 2). 
The SBL-3 MIOL (Lenstec, St. Petersburg, FL) is another asymmetric segmented MIOL that 
is also designed to improve CS, minimize dysphotopsias and provide good far, intermediate 
and near vision. The SBL-3 has a 3D sector-shaped add with a seamless transition zone 
between the distance and near segments. Venter et al. (65) recently published a study 
conducted in 106 eyes showing excellent outcomes (Table 2). 
Rotationally asymmetric MIOLs seem to provide a good visual outcome at distance and near 
with minimal dysphotopsia and retain intermediate. The design minimises loss of light from 
splitting of the incoming light. Patients also were satisfied with their uncorrected near vision. 
Further studies with larger cohorts and longer follow-up period are necessary.  
Finally, Staar (Staar Surgical Company, Monrovia, California) is known to be developing a 
new multi-focal phakic ICL that would potentially correct both ametropia and presbyopia.  
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2.2. Phakic Multifocal Intraocular Lens 
The correction of ametropia and presbyopia can also be corrected using an anterior chamber 
phakic MIOLs. George Baikoff, designed one of the first models (66, 67) and this anterior 
chamber multifocal design has been marketed under the trade names of Newlife (IOLTECH, 
SA, La Rochelle, France) and Vivarte Presbyopic (CibaVision, Duluth, Georgia, USA) and 
provide a single addition of +2.5 D for near vision.  
Baikoff and colleagues also performed the first clinical trial with this type of multifocal IOLs 
in 55 eyes showing that this IOL was effective and gave good predictability. (66) Alio and 
Mulet in another pilot study with a multifocal phakic IOL prototype (AMO, Irvine, 
California, USA) also showed good results (68). However, the complications reported by 
these anterior phakic IOLs include endophthalmitis, surgically induced astigmatism, corneal 
endothelial cell loss, pupil distortion, chronic uveitis, pupillary block glaucoma, pigment 
dispersion syndrome and cataracts. 
III. ACCOMMODATIVE APPROACHES 
For accommodation to be restored in the presbyopic eye, it is necessary that the ciliary 
muscle is still able to contract with accommodative effort: there is evidence to suggest that 
the ciliary muscle does not undergo atrophy with age and remains functional. (69, 70) 
Although the young phakic eye may have 7 to 8 D of true accommodation, most presbyopes 
would be happy with a restoration of 2-3 D of true accommodation. 
 
1. Lenticular Approaches  
1.1. Accommodating Intraocular Lens 
There are many different concepts and designs for AIOLs including mouldable gels, fluid 
displacement and flexible haptics. These IOLs are designed to utilise ciliary muscle 
contraction, capsular bag elasticity and changes in vitreous cavity pressure to induce change 
or movement in the shape of the IOL to produce an optical change in the eye based on the 
optic-shift concept i.e. on the axial movement of the optic resulting from action of the ciliary 
muscle. A hinge between the optic and haptics allows the lens to move forward as the eye 
focuses on near objects and backward as the eye focuses on distant objects, thereby 
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increasing the dioptric power of the pseudophakic eye.  
It has been reported that an IOL optic shift of 1.0mm can offer about 1.0 D of 
accommodation in a single-optic IOL and between 2.5 to 3.0 D in an IOL with 2 lens optics 
(71, 72) In addition, the amount of accommodative result depends on several factors, such as 
the position of the optics in the capsular bag, the posterior chamber and the refractive power 
of the IOL. 
The Crystalens HD [Bausch & Lomb), Rochester, NY] the Tetraflex HD (Lenstec Inc. St. 
Petersburg, FL) and the 1CU Human Optics (Human Optics AG, Erlangen, Germany) are 
examples of single optic AIOLs and have all been extensively used). (73, 74, 75) Visual 
performance reported with these AIOLs is promising (73, 74, 75), however capsule 
opacification and loss of accommodative ability with time are often present. 
 
The single-optic passive-shift IOLs are considered pseudo-accommodative because have 
limited accommodative ability, as its anterior movement is insufficient to provide 
functionally significant amplitudes of accommodation. Hence, dual-optic devices were 
developed such as the Synchrony (AMO, Irvine, CA), and the Sarfarazi IOL (Shenasa 
Medical LLC, Carlsbad, CA). The configuration of these devices with a high positively 
powered mobile anterior optic, connected to a stationary negatively powered posterior optic, 
is designed to increase the potential accommodative amplitude. Published results of both 
IOLs are limited but have shown positive results in small cohorts. (76) They may be 
technically relatively difficult to handle. 
 
In regards with IOLs, which change their shape or curvature with accommodative effort, 
there are some in different stages of development. The FluidVision lens (PowerVision, Inc. 
Belmont, CA) drives fluid of a polymer-matched refractive index from the IOL’s soft haptics 
through channels to a fluid-driven internal activator. One-year follow-up showed that the 
base IOL powers were accurate and stable, visual acuities were good, and patients showed 
more than 5.00 D of accommodation on average (ASCRS 2011). The NuLens (NuLens Ltd., 
Herzliya Pituah, Israel) is a sulcus-based accommodating IOL is still under development 
although it has been implanted in 10 eyes with cataract and atrophic macular degeneration 
showing at 1 year reporting this IOL may result up 10D of accommodation, (77) and the 
Superior Accommodating IOL (Human Optics AG, Erlangen, Germany) is designed to 
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mimic the behaviour of natural lens and it is under development. 
 
The lens filling techniques are being under investigation for years. It consists in replacing the 
lens with a soft gel that would allow modifying the shape for accommodation. The 
Medennium SmartLens IOL (Medennium, Inc. Irvine, CA) is a “smart” hydrophobic acrylic 
material with unique thermodynamic property. When implanted into the capsular bag, the 
body’s temperature causes the material to transform into a gel-like polymer and take the 
shape of the natural lens. To the knowledge of the authors no data has been yet published. It 
should be noted that objective measurement of the accommodative capability of AIOLs is 
extremely difficult to obtain. (78)  
 
 
1.2. Lens Softening 
“Softening” of the less elastic presbyopic crystalline lens is one of the newest approaches to 
restore accommodation. There have been some pharmaceutical attempts to act selectively on 
the lens and soften it, however, to the knowledge of the authors this is not a viable 
alternative. 
The femtosecond laser seeks to restore the flexibility that has been lost by making precise 
incisions patterns within the lens without opening the capsule. 
Pre-clinical studies have been performed in human cadaver and animal lenses (79, 80, 81, 
82) which demonstrated safety, increased flexibility of lens and no production of cataract. A 
feasibility study with the LENSAR (LENSAR INC, Orlando, FL) in 80 subjects with 
cataract showed that one third showed an improvement in objective accommodation 
measured with the Grand Seiko WR-5100K autorefractor  (Grand Seiko Co, Ltd, Fukuyama, 
Japan) and over 50% showed an improvement in subjective accommodation with the push-
down method.  Over 40% also showed an increase in the BDCNVA (results presented at 
ASCRS 2014). 
Currently, there is another femtosecond laser based therapy study for the treatment of 
presbyopia in Germany (The Human Eye study Cologne/Rostock). This clinical study is 
beeing conducted in 2 sites: University of Rostock University Eye Hospital, Rostock, 
Germany and Augenklinik am Neumarkt, Köln, Germany. Fifteen eyes in each site (n = 30 
eyes) have been recruited. However, to the knowledge of the authors, no data has been 
reported. 
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2. Scleral Modification 
Extraocular approaches have been developed based on Schachar’s theory. (83) This model 
states that accommodation results of an increase of zonular traction at the lens equator to 
increase the lens diameter, therefore, presbyopia occurs as a result of increased lens growth 
causing a reduction in the space between the lens and the ciliary body (circumlenticular 
space, CLS), such that upon contraction the zonules can no longer exert their effect on the 
lens due to a loss of tension. Magnetic Resonance Imaging (MRI) studies have shown that 
the CLS decreases with age as a result of the inward movement of the ciliary muscle ring 
that occurs with advancing age and an increase of the lens thickness. (70) However, 
goniovideography, infrared photography and MRI studies have shown that the lens decreases 
in diameter and surface area with accommodation. (84) Despite the controversy of this 
theory, Schachar postulated that expanding the dimensions of the overlying scleral wall, by 
pulling the ciliary muscle away from the equatorial edge of the lens, would reverse the 
process of presbyopia and increase accommodative amplitude. LaserACE (Ace Vision 
Group, Silver Lake, OH) and PresVIEW Scleral Implants (Refocus Group, Dallas, TX) were 
originally developed on the basis of this theory but the actual mechanism of action is still 
under investigation. 
 
2.1. Laser-Assisted Presbyopia Reversal  
Laser assisted presbyopia reversal (LAPR) aims to restore dynamic accommodation 
increasing pliability in the sclera and increasing net forces of the ciliary muscles on the lens 
facilitating accommodation. LAPR mechanism of action objective is decrease the ocular 
rigidity utilizing a hand held fibre optic piece that delivers pulses using an erbium-YAG laser 
to ablate 600-μm laser spots in the sclera, which are presumed to decrease the distance 
between the ora serrata and the scleral spur, restore the anatomical relationships of the 
system and free the ciliary muscle to contract normally. The spots delivered in a diamond 
matrix pattern of 9 laser spots into each oblique quadrant. The results so far (in 134 eyes of 
67 patients after 18 months follow-up are promising. Hipsley reported restoration of 1.25 to 
1.75 D of objective accommodation, which remained stable through 18 months in initial 
results (2011 ASCRS meeting). Table 1 
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2.2. Scleral Expansion Bands 
Scleral expansion band (SEB) surgery for the treatment for presbyopia is based on the model 
of accommodation theorised by Schachar. (83) 
SEBs have therefore been utilised for this purpose, but previous studies have demonstrated 
mixed results and have demonstrated limited success with temporary improvement in 
amplitude of accommodation. (85, 86, 87) Most recently, Refocus group has developed The 
PresView scleral implants. The technique consists of implanting four prostheses (size of a 
grain of rice) within elongated pockets in the sclera. The prostheses are thought to exert 
traction on the sclera in the region overlying the ciliary body which expands the sclera and 
the underlying ciliary body: thus restoring the effective working distance of the ciliary 
muscle and increasing the amplitude of accommodation. The actual surgical technique has 
evolved markedly from the initial use of manual diamond blade to the current use of 
disposable scleratome improving considerably the accuracy of the tunnel creation. 
Furthermore, the original implant was a one-piece device, which was pushed into place and 
was difficult to thread through the tunnel. This one-single piece had a tendency to slip out of 
the tunnel over the long term resulting in a return or regression of patients’ preoperative near 
vision. Nowadays, the implant is a two-piece locking implant that prevents the implant from 
slipping out. Currently, Refocus group is conducting a FDA clinical trial. Table 1 
 
IV. Conclusion 
 
There have been significant developments in surgery for presbyopia over the last decade 
achieving relatively good outcomes but each modality has its own advantages and 
disadvantages and sometimes compromises. However, to properly compare interventions it is 
necessary to encourage researchers to report BDCNVA rather just UCNVA to minimise any 
confounding effect of myopia and astigmatism on results. 
 
Other options for the management of presbyopia should not be forgotten, for example, it has 
been suggested that the use of miotics to increase depth of focus could help those suffering 
from presbyopia, and this would represent a type of reversible treatment. However there is 
little published evidence with this form of treatment, although 200 emmetropic eyes have 
been reported as having been treated in South America. (88) 
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In the next few years it is likely that the introduction of different IOLs will be seen, as well 
as the development of new pharmacological treatments and technologies to provide patients 
with better visual outcomes and then possibly restoration of true accommodation to the 
presbyopic eye will be seen. 
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Author Procedure Study 
Design 
Number of eyes UCNVA BDCNVA Additional tests Complications 
Levinger 
(2013) 
Monovision induced by LASIK 1 year 38 0.06 logMAR 
(binocular 
Not available  CS reduced in mesopic 
condition.  
 Near stereoacuity 57 
seconds of arc 
 85.2% of satisfaction 
Not reported 
Greenbaum  
(2002) 
Monovision pseudophakia 1 year 120 cataract/20 
CLE 
0.0 logMAR or 
better (binocular) 
in 91% cataract 
& 95% CLE 
Not available  91% acceptance 
cataract  
  95% acceptance CLE 
 1 dry eye,  
 1 vitreous loss 
 1 iris atrophy 
 20% reported halos 
& glare in cataract in 
CLE 
Uthoff  
(2012) 
Multifocal corneal ablation 6 months 20 (emmetropic), 
20 (hyperopic), 
20 (myopic) 
0.18 logRAD 
(emmetropic), 
0.24 logRAD 
(hyperopic), 0.12 
logRAD 
(myopic) 
binocular 
Not available CS significantly reduced in 
all groups 
Not reported 
McDonald 
(2004) 
Conductive Keratoplasty 
 
6 months  143 0.18 logMAR or 
better  in 77% 
(monocular) 
Not available 76% reported very 
satisfied/satisfied 
Not reported 
Menassa 
(2012) 
Intrastromal femtosecond Ring  
Incision 
18 months 25 0.2 logMAR 
(monocular) 
Not available Corneal steepening 0.90D  36% reported rings 
aroud light sources  
Limnopoulou 
(2013) 
Flexivue Microlens Inlay 1 year  47 0.14 logMAR 
(monocular), 0.13 
logMAR 
(binocular) 
Not available  HOA increased. 
 CS decreased. 
 81.25% reported 
 UCNVA excellent 
Not surgical 
complications 
Garza (2013) The Raindrop Inlay 1 year  20   <0.1 logMAR 
(monocular & 
binocular) 
Not available  Photopic CS no 
significant change.  
 95% reported satisfied 
or very satisfied 
UCNVA, UCIVA.  
 100%  satisfied or very 
satisfied UCDVA 
 1 patient reported 
severe halos at 6 
months,  
 10% inlays removed 
because 
dissatisfaction, 
decentation. 
Seyeddain 
(2013) 
The Kamra Inlay 2 years 
prospective 
24 0.1 logMAR 
(monocular) 
Not available  0.1 logMAR UCIVA 
 
 1 eye with epitheial 
ingrowth in the 
pocket 
 1eye with epitheial 
iron deposit 
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*Note: some visual acuities were converted to logMAR using the Visual acuity conversion chart prepared by Jack T Holland 
 
LogMAR: Log Minimum Angle of Resolution 
CLE: Clear Lens Extraction 
UCNVA: Uncorrected near visual acuity 
BDCNVA: Best distance corrected near visual acuity 
CS: Contrast Sensitivity 
HOA: High order aberration 
UCIVA: Uncorrected intermidiate visual acuity 
 
Table 1. Visual outcomes of Presbyopia procedures 
 
Baily    
(2014) 
The Icolens corneal inlay 1 year 52 0.4 logMAR 
(monocular) 
Not available 90% reported happy with 
the procedure 
11 inlay explanted 
because minimal 
improvement UCNVA 
Hipsley 
(ASCRS 
2011) 
The LaserACE procedure 18 months  134 0.18 logMAR or 
better in 89% 
Not available  1.25-1.75D increase in 
objective 
accommodation. 
 0.18 logMAR or better 
in 95% UCIVA 
No major complications  
Sunil Shah PresVIEWTM Scleral Implant  3 months 
(on going 2 
years FDA 
clinical trial) 
28 Not available 0.3 logMAR 100% 
(monocular, binocular) 
Mean lines of improvement 
at near 2.3 monocular & 2.0 
binocular  
Not reported 
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Author IOL Design Study                      
Design 
Number of 
eyes 
UCNVA BDCNVA Additional tests Complications 
Forte  
(2009) 
ReZoom Refractive 2 years  55 0.10 logMAR 
(monocular) 
Not available  UCIVA 0.07 logMAR (monocular).  
 7% patients reported moderate glare  
 5% patients reported moderate halo 
Not reported 
Cezon 
(2010) 
Rayner M-flex Refractive 1 year  32 0.28 logMAR 
(monocular) 
0.28 logMAR 
(monocular) 
 UCIVA 0.15 logMAR 
 CIVA 0.15 logMAR (monocular).  
Not reported 
Kohnen 
(2006) 
AcrySof ReSTOR 
MA60D3 
 
Diffractive 6 months 127 0.14 logMAR  
in 66.9% 
(binocular) 
0.14 logMAR  
in 71.2% 
(binocular) 
 84.6% spectacle independence for near 
 8.5% patients reported severe glare 
 4.2% patients reported severe halo 
 2 eyes implants replacement 
 2 eyes with cystoid macular edema 
 1 eye flat macular edema 
 1 eye macular edema with fibrous reaction 
 1 cystic maculopathy 
Packer 
(2010) 
Tecnis multifocal  Diffractive  1 year  244 0.20 logMAR 
(monocular) 
0.10 logMAR    
(binocular) 
 
0.18 logMAR  
(monocular) 
0.10 logMAR    
(binocular) 
 
 95.5% spectacle independency for distance 
 86.6% spectacle independency for near 
 94.6% satisfied 
 10.3% patients reported moderate glare 
 2.6% patients reported severe glare 
 84.8% spectacle independence  
 1 pupilloplasty 
 4 IOL explantation 
 12.8% eyes required Yag laser 
Mojzis 
(2014) 
AT Lisa tri 839MP Diffractive 
trifocal 
6 months 60 0.20 logMAR 
(monocular) 
0.17 logMAR 
(monocular)  
 UCIVA 0.08 logMAR 
 DCIVA 0.08 logMAR (monocular) 
Not surgical complications 
Sheppard 
(2013) 
Finevision trifocal  Diffractive 
trifocal 
2 months 30 Not available Not available  UCDVA 0.19 logMAR (monocular)  
 NAVQ Rasch scores satisfaction at near 15.9 logits 
Not reported 
Voskresens
kaya (2010) 
MIOL-Record trifocal  Diffractive 
trifocal 
6 months  36 0.10 logMAR 
(monocular) 
0.10 logMAR 
(monocular) 
 
 UCIVA, DCIVA 0.2 logMAR, Scotopic 
 CS 0.2 log unit below standard values at all spatial 
frequencies 
 98% patient’s spectacle freedom 
 25% patients reported halos 
Not surgical complications 
Shah 
(2014) 
Lentis Mplus X  LS-313 Rotationally 
asymmetric 
3 months 34 0.18 logMAR 
(monocular) 
0.15 logMAR 
(monocular) 
NAVQ Rasch scores satisfaction at near 20.43 logits Not surgical complications 
Venter 
(2014) 
SBL-3  Rotationally 
asymmetric 
3 months 106 0.12 logMAR 
(monocular); 
0.08 logMAR 
(binocular) 
 
0.11 logMAR 
(monocular); 
0.08 logMAR 
(binocular); 
 
 UCIVA 0.16 logMAR (monocular) & 0.13 logMAR 
(binocular) 
 DCIVA 0.15 logMAR (monocular) & 0.1 logMAR 
)(binocular) 
 94.4% satisfied or very satisfied 
 86.8% had no difficulty at all or little difficulty 
performing tasks that require good close up vision 
Not surgical complications 
Baikoff 
(2004) 
 
Anterior pIOL Refractive 1 year 55 0.23 logMAR 
(monocular) 
 
Not available  Efficacy ratio of 80% 
 Safety ratio of 94% 
 Slight pupil ovalization in 10% eyes 
  Mean endothelium cell loss less than 5% 
 4 IOL explantation because dissatisfaction  
Alio (2005) 
 
 The AMO multifocal   
phakic IOL prototype 
Refractive 1 year 34 0.20 logMAR 
(binocular) 
Not available  UCIVA 0.00 (binocular) 
 Steropsis near 80.62 seconds of arc 
 Patient satisfaction very good in 88% patients 
Not surgical complications 
Cumming Crystalens AT-45 Accommodati 1 year FDA 263 eyes 0.20 logMAR 0.20 logMAR  DCIVA 0.1 in 95% eyes (binocular)  Endophthalmitis 1 eye 
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*Note: some visual acuities were converted to logMAR using the Visual acuity conversion chart prepared by Jack T Holland 
LogMAR: Log Minimum Angle of Resolution 
CLE: Clear Lens Extraction 
UCNVA: Uncorrected near visual acuity 
BDCNVA: Best distance corrected near visual acuity 
UCIVA: Uncorrected intermidiate visual acuity 
CIVA: Corrected intermidiate visual acuity 
DCIVA: Distance corrected intermidiate visual acuity 
AA Amplitude of Accommodation 
CS: Contrast Sensitivity 
HOA: High order aberration 
Table 2. Visual results of intraocular lenses 
 
 
 
(2006) ve clinical trial or better in 
93.5% 
(binocular) 
or better in 
83.9% 
(binocular) 
 25.8% patient’s spectacle freedom  12 eyes IOL dislocation 
 2 eye retinal detachment 
 1 eye iridectomy 
  1 eyes with persistent corneal edema 
  3 eyes with iritis 
Sanders 
(2010) 
Tetraflex Accommodati
ve 
1 year FDA 
clinical 
study 
255 0.4 logMAR in 
77% 
0.4 logMAR or 
better in 67% 
 90% could read ≥ 80 wpm at the 0.2 logMAR print 
size 
 75% patients reported never or occasionally wore 
near glasses  
Malpositioning of 5 IOLS  
Mastropasq
ua (2007) 
1CU Human Optics Accommodati
ve 
2 years 14 Not available 0.2 logMAR at 
6 months 0.48 
logMAR at 2 
years 
AA 1.9D at 6 months and 0.30D at 2 years Anterior & posterior opacification in 100% of cases 
Alio (2009) The NuLens Accommodati
ve 
1 year 10 
(Cataract & 
atrophic 
macular 
degeneratio
n) 
Increase of 3.8 
Jaeger rows (6 
months) 
Not available Cross-section measurement of IOL of 0.09 mm 
(equivalent to 10D) 
 1 posterior synechia inducing IOL tilt 
 1 capsulorhexis edge capture by the haptic ednplate 
inducing high myopia 
